Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076368 | 0.82 | PARP1 (0.45) | PARP1KAT2BSYK | |
| SCHEMBL6327259 | 0.80 | MTNR1A (0.44) | PARP1AURKBALDH1A1MAPK1KAT2B | |
| SCHEMBL6323949 | 0.78 | ALDH1A1 (0.44) | PARP1KDM4EAURKBALDH1A1MAPK1 | |
| SCHEMBL6473156 | 0.78 | PARP1 (0.45) | PARP1KDM4EAURKBALDH1A1KAT2B | |
| SCHEMBL6448886 | 0.72 | SYK (0.44) | PARP1SYK | |
| SCHEMBL5077387 | 0.71 | KAT2B (0.35) | PARP1KDM4EALDH1A1MAPK1KAT2B | |
| SCHEMBL6328281 | 0.71 | GAA (0.49) | KDM4EALDH1A1MAPK1 | |
| SCHEMBL6326353 | 0.70 | EPHX2 (0.41) | AURKBMAPK1 | |
| SCHEMBL6327186 | 0.69 | CD38 (0.41) | PARP1RPS6KB1AURKBKAT2B | |
| SCHEMBL6334650 | 0.68 | ALDH1A1 (0.44) | KDM4EAURKBALDH1A1MAPK1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | PARP1 1/4885RPS6KB1 813/4885KDM4E 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.